[Zhongsheng Pharmaceutical: Phase III clinical trial of the first-class innovative drug RAY1225 for weight loss reaches the primary endpoint] On October 8, Zhongsheng Pharmaceutical (002317.SZ) announced that the phase III clinical trial (REBUILDING-2) of the first-class innovative peptide drug RAY1225 injection independently developed by its holding subsidiary Zhongsheng Ruichuang in overweight or obese participants has obtained top-line analysis data and reached the primary endpoint. The results showed that the body weight of the RAY1225 injection 9 mg group was reduced by 22.24% compared with the baseline, and by 20.46% after placebo correction. The weight loss target rate and the improvement of cardiovascular and metabolic indicators were significantly better than the placebo, and the safety was good. The company reminds that the complete results are subject to the final clinical summary report, and there is uncertainty in the drug launch.